Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, Irvine, CA, USA.
Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
Nat Biomed Eng. 2021 Feb;5(2):169-178. doi: 10.1038/s41551-020-00632-6. Epub 2020 Oct 19.
Cytosine base editors and adenine base editors (ABEs) can correct point mutations predictably and independent of Cas9-induced double-stranded DNA breaks (which causes substantial indel formation) and homology-directed repair (which typically leads to low editing efficiency). Here, we show, in adult mice, that a subretinal injection of a lentivirus expressing an ABE and a single-guide RNA targeting a de novo nonsense mutation in the Rpe65 gene corrects the pathogenic mutation with up to 29% efficiency and with minimal formation of indel and off-target mutations, despite the absence of the canonical NGG sequence as a protospacer-adjacent motif. The ABE-treated mice displayed restored RPE65 expression and retinoid isomerase activity, and near-normal levels of retinal and visual functions. Our findings motivate the further testing of ABEs for the treatment of inherited retinal diseases and for the correction of pathological mutations with non-canonical protospacer-adjacent motifs.
胞嘧啶碱基编辑器和腺嘌呤碱基编辑器 (ABEs) 可以预测性地纠正点突变,而无需 Cas9 诱导的双链 DNA 断裂(这会导致大量插入缺失形成)和同源定向修复(通常导致低编辑效率)。在这里,我们在成年小鼠中表明,通过视网膜下注射表达 ABE 和靶向 Rpe65 基因中新发无义突变的单指导 RNA 的慢病毒,可以以高达 29%的效率纠正致病突变,并且最小化插入缺失和脱靶突变的形成,尽管缺乏作为前间隔基序相邻基序的典型 NGG 序列。ABE 处理的小鼠表现出恢复的 RPE65 表达和视黄醇异构酶活性,以及接近正常水平的视网膜和视觉功能。我们的发现促使进一步测试 ABE 用于治疗遗传性视网膜疾病和纠正具有非典型前间隔基序相邻基序的病理性突变。